Trial Profile
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Mar 2024
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Alopecia areata
- Focus Registrational; Therapeutic Use
- Acronyms BRAVE-AA-PEDS
- Sponsors Eli Lilly and Company
- 17 Jan 2024 Planned primary completion date changed from 6 Nov 2024 to 9 Apr 2025.
- 12 Apr 2023 Planned primary completion date changed from 9 Apr 2025 to 6 Nov 2024.
- 18 Mar 2023 Status changed from not yet recruiting to recruiting.